Patent US5055289A successfully refreshed from Google Patents.
US5055289A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Interferon antibody therapeutic compositions having an extended serum half-life
Assignee: Hybritech Inc
•
Filing: 1988-08-19
•
Granted: 1991-10-08
•
Expires: 2008-08-19
Abstract
Abstract A complex of alpha-interferon with a monoclonal antibody complexes with the alpha-interferon without impairing its antiviral activity. The serum half-life of the interferon administered as the complex is substantially increased when compared to that of alpha-interferon administered alone.
Inventors
- 👤 James M. Frincke
- 👤 Barbara W. Unger
- 👤 Karen G. Burnett
- 👤 Evan M. Hersh
- 👤 Michael G. Rosenblum
- 👤 Jordan U. Gutterman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 13:53
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/46; C07K16/468; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K39/00; A61K39/395; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6875; A61K47/6879
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
49 words
A composition comprising a non-covalent complex of a therapeutically active agent and an antibody selected to bind said agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the therapeutically active agent, wherein said therapeutically active agent is an interferon.
Claim 2
Dependent Claim
49 words
A composition comprising a non-covalent complex of a therapeutically active agent and an antibody selected to bind said agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the therapeutically active agent, wherein said therapeutically active agent is an interferon.
Claim 3
Dependent Claim
13 words
A composition according to claim 1 wherein the antibody is a monoclonal antibody.
Claim 4
Dependent Claim
15 words
A composition according to claim 1 wherein the antibody comprises a population of polyclonal antibodies.
Claim 5
Dependent Claim
25 words
A composition according to claims 2 and 3 wherein the antibody comprises an antibody fragment selected from the group consisting of Fab, Fab' and Fab'2.
Claim 6
Dependent Claim
35 words
A composition according to claim 1 wherein the antibody is a hybrid monoclonal antibody having a dual specificity one of which is against the therapeutically active agent and the other against a disease associated antigen.
Claim 7
Dependent Claim
20 words
A composition according to claim 5 wherein the hybrid antibody is an antibody fragment selected from Fab, Fab' and Fab'2.
Claim 8
Dependent Claim
17 words
A composition according to claim 1 wherein the interferon is selected from alpha, beta and gamma interferons.
Claim 9
Dependent Claim
31 words
A composition according to claims 5 or 6 wherein one specificity of the hybrid antibody is directed against a tumor associated antigen and the other against the agent having anti-tumor activity.
Claim 10
Dependent Claim
19 words
A composition according to claim 8 wherein the tumor associated antigen is selected from CEA, PAP, PSA, or ferritin.
Claim 11
Dependent Claim
15 words
A composition according to claim 1, 2, 3 or 5 further comprising a pharmaceutical vehicle.
Claim 12
Independent Claim
62 words
A method for treating viral diseases and tumors in an animal comprising parenterally administering thereto an effective amount of a therapeutically active agent and an antibody against said agent which binds the agent noncovalently at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the agent, wherein said therapeutically active agent is an interferon.
Claim 13
Independent Claim
62 words
A method for treating viral diseases and tumors in an animal comprising parenterally administering thereto an effective amount of a therapeutically active agent and an antibody against said agent which binds the agent noncovalently at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the agent, wherein said therapeutically active agent is an interferon.
Claim 14
Dependent Claim
14 words
A method of claim 11 wherein the antibody and agent are combined in vitro.
Claim 15
Dependent Claim
13 words
A method of claim 11 wherein the antibody and agent are separately administered.
Claim 16
Dependent Claim
22 words
A method of claim 13 wherein the antibody is allowed to distribute itself throughout the patient prior to administration of the agent.
Claim 17
Independent Claim
16 words
A method of claims 11, 12, 13 or 14 wherein the antibody is a monoclonal antibody.
Claim 18
Dependent Claim
35 words
A method of claim 15 wherein the monoclonal antibody is a hybrid antibody having a dual specificity one of which is directed against the therapeutically active agent and the other against a disease associated antigen.
Claim 19
Dependent Claim
17 words
A method of claim 15 wherein the antibody is a fragment selected from Fab, Fab' and Fab'2.
Claim 20
Dependent Claim
16 words
A method of claim 11 wherein the interferon is selected from alpha, beta and gamma interferons.
Claim 21
Dependent Claim
19 words
A method of claim 16 wherein the antigen is a tumor associated antigen and the agent has anti-tumor activity.
References Cited (Backward Citations)
US4093607A
Cited
US4520226A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-10-07 | 1995-04-08 | 1995-10-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-10-07 | 1999-04-08 | 1999-10-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-10-07 | 2003-04-08 | 2003-10-08 | $7700.00 | Window Closed / Lapsed |